日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer

ESR1突变转移性乳腺癌中与依拉司特疗效相关的临床和基因组因素

Lloyd, Maxwell R; Weipert, Caroline M; Ali, Azka; Solomon, Sheila R; Saha, Jayati; Lipsyc-Sharf, Marla D; Hamilton, Erika P; Kalinsky, Kevin; Brufsky, Adam M; Bardia, Aditya; Zhang, Nicole; Wander, Seth A

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer

埃拉塞群在ER+、HER2-、ESR1突变型转移性乳腺癌中的真实世界疗效

Rugo, Hope S; Kaklamani, Virginia; McArthur, Heather; Wander, Seth A; Gradishar, William; Mahtani, Reshma; Pegram, Mark; Lustberg, Maryam; Swallow, Elyse; Maitland, Jessica; Kloss, Sebastian; Wasserman, Tomer; Tolaney, Sara M

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

阿贝西利联合氟维司群治疗CDK4/6抑制剂治疗进展后的晚期乳腺癌:MONARCH III期临床试验结果

Kalinsky, Kevin; Bianchini, Giampaolo; Hamilton, Erika; Graff, Stephanie L; Park, Kyong Hwa; Jeselsohn, Rinath; Demirci, Umut; Martin, Miguel; Layman, Rachel M; Hurvitz, Sara A; Sammons, Sarah; Kaufman, Peter A; Muñoz, Montserrat; Lai, Jiun-I; Knoderer, Holly; Sandoval, Cynthia; Chawla, Aarti R; Nguyen, Bastien; Zhou, Yanhong; Ravenberg, Elizabeth; Litchfield, Lacey M; Smyth, Lillian; Wander, Seth A

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.

从临床到实验室的转化分析:激素受体阳性转移性乳腺癌中 NF1 改变和 CDK4/6 抑制剂耐药性

Lloyd Maxwell R, Chica-Parrado Rosario, Weipert Caroline M, Knepper Todd C, Podany Emily L, Napolitano Fabiana, Ye Dan, Lin Chang-Ching, Uemoto Yasuaki, Liao Jiemin, Wegrzyn Claire, Walko Christine M, Ryan Lianne Y, Keenan Jennifer C, Medford Arielle J, Liu Shiyuan A, Wulf Gerburg M, Clifton Katherine K, Ma Cynthia X, Han Hyo S, Zhang Nicole, Ellisen Leif W, Bardia Aditya, Arteaga Carlos L, Hanker Ariella B, Wander Seth A

Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

格达托利西布联合帕博西尼和来曲唑治疗既往未接受过全身治疗的激素受体阳性、HER2阴性晚期乳腺癌患者

Wesolowski, Robert; Rugo, Hope S; Specht, Jennifer M; Han, Hyo S; Kabos, Peter; Vaishampayan, Ulka; Wander, Seth A; Gogineni, Keerthi; Spira, Alexander; Schott, Anne F; Abu-Khalaf, Maysa; Mutka, Sarah C; Suzuki, Samuel; Sullivan, Brian; Gorbatchevsky, Igor; Layman, Rachel M

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

转移性乳腺癌患者中TOP1突变和抗体药物偶联物的交叉耐药性

Abelman Rachel O, Wu Bogang, Barnes Haley, Medford Arielle, Norden Bryanna, Putur Annika, Bitman Elena, Thant Win, Liu Ting, Weipert Caroline, Fell Geoffrey, Spring Laura M, Wander Seth A, Moy Beverly, Vidula Neelima, Isakoff Steven J, Varkaris Andreas, Juric Dejan, Corcoran Ryan B, Ellisen Leif W, Bardia Aditya

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)

使用细胞周期蛋白依赖性激酶 4/6 抑制剂 ribociclib 进行辅助内分泌治疗,用于治疗局部激素受体阳性/HER2- 乳腺癌(LEADER)

Spring, Laura M; Scarpetti, Lauren; Medford, Arielle J; Niemierko, Andrzej; Comander, Amy; Mulvey, Therese; Schnipper, Lowell; Isakoff, Steven J; Moy, Beverly; Wander, Seth A; Shin, Jennifer; Ephrem, Zanta; Laposta, Anneke R; Denault, Elyssa; Abraham, Elizabeth; Calistro, Gayle; Kalashnikova, Ekaterina; Rodriguez, Angel; Liu, Minetta C; Aleshin, Alexey; Peppercorn, Jeffrey; Ellisen, Leif W; Bardia, Aditya

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

三阴性乳腺癌(TNBC)患者中HER2低表达状态的动态变化及其对重复活检的影响

Bar, Yael; Fell, Geoffrey; Dedeoglu, Aylin; Moffett, Natalie; Vidula, Neelima; Spring, Laura; Wander, Seth A; Bardia, Aditya; Ko, Naomi; Moy, Beverly; Ellisen, Leif W; Isakoff, Steven J

Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer

一线与二线 CDK4/6 抑制剂治疗激素受体阳性、HER2 阴性转移性乳腺癌的疗效比较

Ravani, Lis Victoria; Bagheri, Zahra; Brufsky, Adam M; Michelon, Isabella; O'Regan, Ruth; Lustberg, Maryam; Han, Hyo; Wang, Ming; Wander, Seth A

OR04-08 Ligand Class Analysis Enables Predictive Models for Effective Antagonism of Endocrine Resistant Breast Cancer

OR04-08 配体类别分析可构建预测模型,有效拮抗内分泌耐药性乳腺癌

Ravani, Victoria Lis; Bagheri, Zahra; Brufsky, Adam M; Michelon, Isabella; O'Regan, Ruth; Lustberg, Maryam; Han, Hyo; Wang, Ming; Wander, Seth A; Nwachukwu, Jerome C; Min, Charles K; Kobylski, Robin R; Kim, Tahchur J; Hou, Yingwei; Kim, Sung Hoon; Hancock, Govinda R; Izard, Tina; Fanning, Sean W; Katzenellenbogen, Benita S; Katzenellenbogen, John A; Nettles, Kendall W